Market Place
Sourcing Support
Samsung Bioepis Report: Biosimilars Surge With 92 US Approvals
28 Apr 2026 //
INDPHARMAPOST
Established Samsung Epis to Drive Growth for Samsung Bioepis
02 Nov 2025 //
BUSINESSWIRE
Samsung Bioepis Phrontline Partner For ADCs In Solid Tumors
20 Oct 2025 //
BUSINESSWIRE
Kyung-Ah Kim Named as President & CEO of Samsung Bioepis
27 Nov 2024 //
GLOBENEWSWIRE
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
11 Jul 2024 //
GLOBENEWSWIRE
Samsung Bioepis’ PYZCHIVA Approved by FDA as Biosimilar of Stelara
01 Jul 2024 //
CONTRACT PHARMA
Samsung Bioepis Releases 2024 Sustainability Report on Accessibility and R&D
25 Jun 2024 //
GLOBENEWSWIRE
Samsung Bioepis Presents EPYSQLI Post-Hoc Analysis At EHA
14 Jun 2024 //
GLOBENEWSWIRE
Novartis, Roche unit and others face Italy antitrust probe over eye drug
07 Jun 2024 //
REUTERS
Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio
09 Mar 2024 //
GLOBENEWSWIRE
Samsung Bioepis Secures US License Date for SB17
30 Nov 2023 //
GLOBENEWSWIRE
Organon, Samsung launch copycat for arthritis drug Humira at 85% discount
03 Jul 2023 //
REUTERS
Samsung Bioepis Releases 2023 Sustainability Report
30 Jun 2023 //
GLOBENEWSWIRE
Samsung Bioepis Presents Data from its Ophthalmology Biosimilar Portfolio
27 Sep 2022 //
GLOBENEWSWIRE
Samsung Bioepis Presents Three-year Follow-up Data of Adalimumab Biosimilar SB5
07 Sep 2022 //
GLOBENEWSWIRE
Samsung Bioepis, Organon Bag FDA Approval of Humira Biosimilar, HADLIMA
17 Aug 2022 //
BUSINESSWIRE
Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab)
09 Jun 2022 //
GLOBENEWSWIRE
Changes Afoot in US AMD Market as Prescribers Brace for the Launch of Byooviz
08 Jun 2022 //
PRNEWSWIRE
Biogen launch first US biosimilar with Samsung Bioepis
03 Jun 2022 //
FIERCEPHARMA
Samsung Bioepis Announces New Data on Adalimumab Biosimilar, SB5 at EULAR 2022
31 May 2022 //
GLOBENEWSWIRE
Samsung Biologics completes full acquisition of Samsung Bioepis
20 Apr 2022 //
PRNEWSWIRE
Galera Reports Q4 and FY 2021 Financial Results and Recent Corporate Updates
10 Mar 2022 //
GLOBENEWSWIRE
Health Canada Approves Samsung Bioepis and Biogen`s BYOOVIZ, LUCENTIS Biosimilar
10 Mar 2022 //
GLOBENEWSWIRE
Samsung Bioepis Celebrates 10 Years of Realizing Passion for Health
28 Feb 2022 //
GLOBENEWSWIRE
Biogen sells stake in biosim JV to partner Samsung for $2.3B
29 Jan 2022 //
BIOPHARMADIVE
FDA Accepts Samsung Bioepis’ & Organon’s sBLA for HUMIRA Biosimilar Candidate
05 Jan 2022 //
BUSINESSWIRE
Amgen has delayed the entry of another Enbrel biosimilar
02 Dec 2021 //
FIERCEPHARMA
Biogen bags FDA nod for copycat to Roche`s blockbuster Lucentis
21 Sep 2021 //
FIERCEPHARMA
Samsung Bioepis Announces 5 year Follow-up Results for ONTRUZANT in HPBC
12 Sep 2021 //
GLOBENEWSWIRE
Samsung Bioepis gets nod for sale of ophthalmology biosimilar drug in Europe
23 Aug 2021 //
KEDGLOBAL
Samsung Bioepis sees 30% jump in biosimilar sales in H1
13 Aug 2021 //
KOREAHERALD
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for BYOOVIZ™
25 Jun 2021 //
GLOBENEWSWIRE
Samsung Biologics Signs Agreement with Kahr Medical
03 Jun 2021 //
CONTRACTPHARMA
Samsung Biologics Obtains Four Global ISO Certifications
27 May 2021 //
CONTRACTPHARMA
Moderna, Samsung Biologics Ink COVID Vax Mfg. and Supply Pact
24 May 2021 //
CONTRACTPHARMA
Samsung Bioepis’ Q1 biosimilar sales in Europe hit $205m
23 Apr 2021 //
KOREAHERALD.
Korean firm Samsung Bioepis continues global market expansion
30 Mar 2021 //
BIOSPECTRUMASIA
Samsung Bioepis partners with Yuhan to sell Humira’s biosimilar
15 Mar 2021 //
KOREABIOMED
Samsung`s `Super Plant` won`t be the last of its expansions
19 Jan 2021 //
FIERCEPHARMA
Samsung Bioepis to conduct P3 trials of Prolia biosimilar
14 Dec 2020 //
KOREABIOMED
SAMSUNG BIOEPIS AND BIOGEN ANNOUNCE FDA FILING ACCEPTANCE OF SB11
18 Nov 2020 //
PRESS RELEASE
China launches Bo`ao Winhealth rare disease medical center
18 Nov 2020 //
BIOSPECTRUMASIA
Samsung BioLogics says mass producing Eli Lilly`s COVID-19 treatment
17 Nov 2020 //
REUTERS
Samsung Bioepis Initiates Ph 1 Trial for SB16, Proposed Biosimilar to Prolia
10 Nov 2020 //
PRESS RELEASE
Samsung Bioepis Announces First Real-World Data on RENFLEXIS® (infliximab-abda)
26 Oct 2020 //
GLOBENEWSWIRE
EMA accepts application for ranibizumab biosimilar from Samsung Bioepis
23 Oct 2020 //
GABIONLINE
EMA Reviews Samsung Bioepis’ Lucentis Biosimilar For Eye Diseases
07 Oct 2020 //
BIGMOLECULEWATCH
Biogen files application in Europe for Lucentis biosimilar
06 Oct 2020 //
SEEKING ALPHA
Samsung Bioepis & Biogen Announce EMA Filing Acceptance of SB11
06 Oct 2020 //
BLOOMBERG
Samsung Bioepis Reports Positive Phase 3 Results for Aybintio
16 Sep 2020 //
BIOSIMILARS
Samsung constructing new $2B `Super Plant` roughly the size of America`s malls
04 Sep 2020 //
ENDPTS
Samsung Bioepis Receives European Commission Approval for AYBINTIO®
20 Aug 2020 //
GLOBENEWSWIRE
Samsung Bioepis launches Ontruzant in Brazil
10 Aug 2020 //
THEPHARMALETTER
Samsung Biologics and ImmuneOncia sign multi-product development
15 Jul 2020 //
PRNASIA
Genentech Alleges Infringement by Samsung Bioepis
08 Jul 2020 //
CENTERFORBIOSIMILARS
Samsung Bioepis Begins Phase 3 Trial for Aflibercept Biosimilar
30 Jun 2020 //
CENTERFORBIOSIMILARS
New BPCIA Complaint: Genentech Seeks to Block Samsung Bioepis’s Proposed AVASTIN
30 Jun 2020 //
BIGMOLECULEWATCH
Samsung Bioepis secures positive CHMP opinion for Aybintio
25 Jun 2020 //
PHARMACEUTICAL-TECHNOLOGY
GSK signs $231M Samsung deal to expand biologics manufacturing
23 May 2020 //
FIERCE PHARMA
Samsung Bioepis Announces Four-Year Follow-Up Data for Trastuzumab Biosimilar
20 May 2020 //
BIGMOLECULEWATCH
